temozolomideGBMGlioblastomaTMZmPIIB
…rammed iAPCs and GFP-transduced controls were then treated with temozolomide (100µM, 72h) or TTFields (200kHz, 1.5V/cm, 72h), and pyroptosis…
Browse by entity family
An entity family is a category of extracted information. Choose one to browse its named entities and supporting articles.
Funders
Organisations named as supporting, sponsoring, or funding research.
5,089 articles · 9,137 mentionsInstitutionsUniversities, hospitals, research centres, networks, and public bodies.
11,350 articles · 22,378 mentionsDrugsNamed medicines, compounds, vaccines, and pharmacological agents.
10,506 articles · 58,393 mentionsDiseasesNamed diseases, disorders, syndromes, injuries, and health conditions.
23,712 articles · 125,551 mentionsTreatmentsClinical therapies and care approaches used to manage a condition.
7,227 articles · 16,644 mentionsInterventionsProgrammes, procedures, policies, and other actions being evaluated.
4,132 articles · 9,994 mentionsClinical instrumentsNamed questionnaires, scales, scores, indices, and other clinical outcome assessments.
945 articles · 1,957 mentions29,499matching articles
244,054matching entity mentions
30popular entities listed
0%of mentions human-reviewed
Popular entities in these results
Choose an entity to see the articles in which it was identified.
EMBASE784PUBMED717COVID-19645Cancer605SLE570Diabetes552NHS522WEB OF SCIENCE499Hypertension418SCOPUS417HIV406Systemic Lupus Erythematosus390Heart Failure364Asthma349Stroke336COPD331WHO330Colorectal Cancer327Cardiovascular Disease317Type 2 Diabetes316Chronic Obstructive Pulmonary Disease313Joanna Briggs Institute306MEDLINE306Atrial Fibrillation283Cochrane Library275Breast Cancer271Hepatocellular Carcinoma253SSc251Inflammatory Bowel Disease250Obesity246
Matching articles
29,499 articles · page 395 of 2459Cytokine release syndromeOKT3TransCure bioServicesCRSimmune checkpoint inhibitorsT cell engagers
…Background Cytokine release syndrome (CRS) is a serious immune-related toxicity frequently associate…
immune checkpoint inhibitorsUMass Chan Medical SchoolirAEimmune-related adverse events
…Background With expanding use of immune checkpoint inhibitors, the incidence of immune-related adverse events (irAE) is on th…
pembrolizumabdurvalumabnivolumabatezolizumabTNBCtriple-negative breast cancerTriNetX
… TNBC (ER-/PR-/HER2-) who received at least one dose of an ICI (pembrolizumab, atezolizumab, nivolumab, or durvalumab) between 2014 and 2025.…
EVM14
… the antigen-expressing tumor cells in mice. The combination of EVM14 with ICIs significantly enhanced the anti-tumor activity. EVM14…
National Cancer InstituteNCIbispecific antibodiesimmune checkpoint inhibitorsimmunotherapiesNCI SBIR
…esses in research and development. The SBIR/STTR program at the National Cancer Institute (NCI) plays a unique role in providing essential seed funding t…
UPMC Hillman Cancer CenterHead and Neck Squamous Cell CarcinomaIOimmunotherapyHNSCCstartup funds
…eir families for participating in this study. Finally, we thank UPMC Hillman Cancer Center for startup funds for this project.References Cillo AR, et al. …
MelanomaFox Chase Cancer CenterPROS1
…Background Melanoma incidence, metastasis, and mortality are significantly associat…
CytoChexTransfixsodium heparin
…days at 4°C) but is not optimal for storage longer than 3 days. CytoChex underperforms in preserving key immune cell populations. TokuKi…
ipilimumabmelanomadermatitisinterferon alfa-2b
…treicher H, Sondak VK, Kirkwood JM. Phase III study of adjuvant ipilimumab (3 or 10 mg/kg) versus high-dose interferon alfa-2b for resecte…
TNBCandrogen receptor antagonistsneoadjuvant chemotherapyClinicalTrials.govtriple-negative breast cancersEMBASEMEDLINE
…clusions AR positivity identifies a chemoresistant, immune-cold TNBC subtype with substantially lower pathologic complete response t…